Logo

BMS Receives the CHMP’s Positive Opinion for Abecma (idecabtagene vicleucel) to Treat Multiple Myeloma

Share this
BMS

BMS Receives the CHMP’s Positive Opinion for Abecma (idecabtagene vicleucel) to Treat Multiple Myeloma

Shots:

  • The CHMP positive opinion was based on the results from the P-III (KarMMa-3) clinical trial evaluating Abecma vs standard regimens in patients with r/r multiple myeloma following 2-4 prior lines of therapy. The 1EP of the study was PFS & 2EPs were ORR & OS
  • Following a median follow-up of 30.9mos., the study showed a PFS of 13.8mos. vs 4.4mos., depicting a 51% reduction in risk of disease progression or deah with Abecma, along with an ORR of 71% vs 41% with CR in 44% vs 5%. The results were presented at the ASH Annual Meeting in Dec 2023
  • Abecma is a CAR T cell therapy that functions by recognizing & binding to the surface of multiple myeloma cells & thereby causing CAR T cell proliferation, cytokine secretion & subsequent cytolytic killing of BCMA-expressing cells

Ref: BMS | Image: BMS

Related News:- BMS’ Abecma (idecabtagene vicleucel) Receives sNDA Approval as Early Lines of Therapy for R/R Multiple Myeloma (RRMM) in Japan

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com

Click here to­ read the full press release 

Shivani Chandra

Shivani was a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She was covering news related to Product approvals, clinical trial results, and updates. We can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions